Academic Editor: Peter A. McCullough
Transradial access for PCI (TRI) along with same day discharge (SDD) is
associated with varying estimates of cost savings depending on the population
studied, the clinical scenario and application to low-risk vs high-risk patients.
A summary estimate of the true cost savings of TRI and SDD are unknown. We
searched the PubMed, EMBASE®, CINAHL® and Google
Scholar® databases for published studies on hospitalization costs
of TRI and SDD. Primary outcome of interest in all included studies was the cost
saving with TRI (or SDD), inflation-corrected US
The practice of percutaneous coronary intervention (PCI) in the United States is evolving. Over 25 years ago, Campeau in Canada contemporaneous with Kiemeneij and Laarman in The Netherlands, began explorations into the possibility of using transradial access [1, 2, 3, 4, 5, 6, 7]. Since then rapid advances in this technique and related devices have catapulted transradial intervention (TRI) to an internationally accepted benchmark and a clinically viable approach to PCIs [8, 9, 10, 11]. A series of studies have demonstrated the superiority of TRI compared to conventional transfemoral intervention (TFI) in terms of reduced risk of adverse outcomes and shorter lengths of hospital stays [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]. A recent Scientific Statement from the American Heart Association highlights these advantages and recommends TRI even in patients with acute coronary syndrome (ACS) [24]. Additionally, over a decade ago, Society for Cardiovascular Angiography and Interventions (SCAI) published an expert consensus in the form a decision matrix to facilitate same-day discharge (SDD) after PCI [25]. Being especially suited for TRI, this SDD approach is highly attractive to patients, physicians and hospitals [26, 27, 28]. A recent meta-analysis has shown that in patients with stable coronary artery disease, SDD is not associated with adverse outcomes. The SDD approach has thus led to reduced practice variations around post-PCI care without affecting the rates of adverse outcomes after PCI [28, 29, 30, 31].
Both TRI and SDD have added economic benefits and have been shown to reduce costs associated with PCI [1, 32, 33, 34, 35, 36, 37, 38, 39, 40]. From the perspective of the hospitals, better resource utilization and shorter duration of hospital stay can yield substantial reductions in hospitalization costs. While there is a paucity of controlled trials that specifically address hospitalization costs in the context of TRI and SDD, several observational studies have demonstrated reduced hospitalization costs in this regard [15, 32, 33, 34, 36, 41, 42, 43]. However, these studies have provided varying estimates of cost savings depending on the population studied, the clinical scenario and application to low-risk vs high-risk patients. Accordingly, the true cost savings of TRI and SDD have not been defined. To address this knowledge gap, we report our results from a systematic review and meta-analytic synthesis of the published literature on the estimated economic impact of TRI and SDD in the United States. Our objectives were twofold: to determine a meta-analytic summary estimate of the cost savings associated with TRI and SDD; and to investigate the heterogeneity across studies in cost-savings associated with TRI or SDD.
We searched the PubMed, EMBASE®, CINAHL® and Google Scholar® databases for published studies on hospitalization costs of TRI and SDD. Fig. 1 shows the flowchart used to include studies into this systematic review and meta-analysis. A combination of literature search and snowballing methods were used to include potential studies into this review. Each included study was independently reviewed by the two coauthors (AA and HK) for completeness and to extract the information needed for meta-analysis. We included all published studies related to cost savings of TRI or SDD in the systematic review but for the meta-analyses we restricted to the US studies only to avoid comparisons across different healthcare models.
Protocol for including studies in this systematic review and meta-analysis. Black boxes indicate studies that were included in the meta-analyses. N, number of articles.
Primary outcome of interest in all included studies was the absolute cost
savings associated with TRI or SDD. Since the studies have been published at
different times, we first converted the cost estimates reported by individual
studies into inflation-corrected 2018 United States dollar (US
For meta-analytic synthesis, we used Hedges’ summary estimate (g) [46] in a
random effects framework of the DerSimonian and Laird model [47]. Inverse
variance weights were used to compute the summary estimates. Heterogeneity was
quantified using the I
In 1996, Mann et al. [51] published the first
cost-effectiveness study of TRI. The primary outcome in this study was the
hospital charge of TRI as compared to TFI and it was found that in a randomized,
controlled setting of 152 PCIs, the hospital charge for TRI procedures was
significantly lower than that for TFI (
A prior meta-analysis [24] published in 2012 on the heels of an earlier
meta-analytic cost-benefit analysis [53] has detailed the economic benefits of
TRI over TFI. For example, it has been shown that the lower complication rates
and shorter hemostasis time associated with radial access are sufficient to
offset the comparable (or potentially longer) procedural time and higher
crossover rates such that there is a net estimated direct cost saving of
A year after this meta-analysis was published, Safley et al. [54] used a propensity-matched analysis from a large, nationally representative
repository and estimated the per-patient saving of
Fig. 2A shows a forest plot of the four US studies on TRI-related cost savings
that were included in meta-analyses. Table 1 shows that these studies came from
widely varying patient sources-single center, Premier Healthcare database, NCDR
CathPCI for 5 hospitals and Medicare beneficiaries. These studies generally
reported a consistent and significant cost saving associated with TRI that ranged
from US
Meta-analysis of the cost savings of TRI. (A) Forest plot of the published studies. Each study is color-coded. Boxes are proportional to the inverse-variance weights; error bars indicate 95% confidence intervals. Diamond represents the summary effect size. (B) Boujat plot for the studies included in meta-analysis. Studies are color-coded and numbered to match the scheme in panel A.
Study | Year | Type of study | N | Patient source | Prevalence of TRI | Cost period | Cost of TRI/SDD | Cost of TFI/NSDD | Inclusion/Exclusion | Study period | Dollar year | Cost reduction | 2018 cost reduction | ||||
Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||||||||||
Studies on cost saving of TRI | |||||||||||||||||
Applegate et al. | 2013 | Observational | 1,140 | Wake Forest Baptist Medical Center, Winston-Salem, NC | 0.5 | Hospitalization | 15,186 | 4,803 | 15,918 | 5,234 | PCIs after Sep 2009, elective only, no STEMI, no CABG, propensity matching | Jan. 2009–Dec. 2011 | 2010 | 732 | 288 | 914 | 360 |
Safley et al. | 2013 | Observational | 61,509 | Premier Healthcare Database | 0.0909 | Hospitalization | 11,736 | 268 | 12,288 | 393 | All patients, single PCI, single stent, no CS, no data on MI status | 2004–2009 | 2012 | 552 | 254 | 645 | 297 |
Amin et al. | 2013 | Observational | 7,121 | NCDR (5 hospitals) | 0.1712 | Hospitalization | 14,954 | 204 | 15,784 | 161 | PCIs at study centers, single PCI, no CS, no CTO | Jan. 2010–Mar. 2011 | 2011 | 830 | 267 | 1,006 | 324 |
Amin et al. | 2017 | Observational | 279,987 | Medicare beneficiaries | 0.0904 | Hospitalization | 15,786 | 72 | 16,701 | 41 | All matching claims, no ACS, no CTO, no CS, no CA | Jul. 2009–Dec. 2012 | 2014 | 915 | 71 | 1,020 | 79 |
Studies on cost saving of SDD | |||||||||||||||||
Amin et al. | 2017 | Observational | 279,987 | Medicare beneficiaries | 0.0529 | Hospitalization | 13,256 | 83 | 16,753 | 40 | All matching claims, no ACS, no CTO, no CS, no CA | Jul. 2009–Dec. 2012 | 2014 | 3,502 | 78 | 3,902 | 86 |
Amin et al. | 2018 | Observational | 672,470 | Premier Healthcare Database | 0.0906 | Hospitalization | Not reported | Elective PCIs | Jan. 2006–Dec. 2015 | 2016 | 5,128 | 61 | 5,364 | 64 | |||
Amin et al. | 2018 | Observational | 1,752 | Single center NCDR CathPCI data | 0.1312 | Hospitalization | Not reported | Elective PCIs | Jul. 2009–Sept. 2015 | 2016 | 7,331 | 1,481 | 7,668 | 1,549 | |||
Rodriguez-Araujo et al. | 2018 | Observational | 490 | Single center registry | 0.5 | 30 days | 4,493 | 119 | 7,112 | 267 | Elective, transradial PCIs from RASSADA PCI trial | 2018 | 2,619 | 293 | 2,621 | 293 | |
Kwok et al. | 2019 | Observational | 324,345 | NRD repository | 0.0157 | 30 days | 15,063 | 109 | 16,968 | 34 | Elective PCIs, no MCS, no CS, no CABG | 2010–2014 | 2012 | 1,905 | 114 | 2,227 | 133 |
Rymer et al. | 2019 | Observational | 2,184 | VA CART repository | 0.33 | 30 days | 23,656 | 574 | 25,878 | 458 | First, unstaged, elective PCI, no weekend adm, no urgent or salvage procedures, no in-lab complications | Oct. 2008–Sep. 2016 | 2016 | 1,503 | 383 | 1,572 | 400 |
Table 2 shows the evidence for significant cost savings associated with TRI use as reported by studies around the world. There have been 7 published studies [15, 56, 57, 58, 59, 60, 61] that have reported cost differential in TRI and TFI-3 studies from China [58, 59, 60] and 1 each from France [56], Mexico [57], Poland [15] and England [61]. Irrespective of the country where from a study was reported, there was a consistent observation of a reduced cost associated with TRI. For international cost savings, the international currency conversion rates, varying payment systems, and different publication years of these studies make it difficult to arrive at a standardized estimate of cost saving that is comparable across the datasets but the consistency of derived estimates of cost savings in these studies is evident. Data presented in these studies again demonstrate reduced rates of complications as the primary driver rather than procedural cost differences. For example, in a small trial, Dziki et al. [62] demonstrated comparable procedural cath lab costs when comparing TRI to TFI. Finally, it is noteworthy that the recent, large study [61] from England again demonstrated that the TRI costs are even lower in STEMI patients (348£) as compared to stable CAD patients (153£)—a finding that is concordant with the Safley et al. [54] and Amin et al. [55] studies from the US implying that the cost savings tend to be higher in high-risk patients. Together these studies corroborate the results of meta-analysis of the US studies presented in Fig. 2A.
Study | Year | Type of study | N | Country | Prevalence of TRI | Inclusion/Exclusion | Cost reduction | Currency |
CARAFE | 2001 | RCT | 210 | France | 0.66 | All PCIs, no MI, no CABG, no RHC | 586.5 | ₣ |
Escárcega et al. | 2010 | Observational | 174 | Mexico | 131 stable coronary patients, 43 ACS patients | 509.0 | ||
Jin et al. | 2016 | Observational | 5,306 | China | 0.885 | Single center, single PCI, no CS, no CTO, no IABP | 8,081.0 | ¥ |
Koltowski et al. | 2016 | RCT | 103 | Poland | 0.5 | STEMI patients from OCEAN RACE trial | 314.0 | € |
Jin et al. | 2017 | Observational | 1,229 | China | Elderly patients | 7,495.0 | ¥ | |
Jin et al. | 2017 | Observational | 1,392 | China | Women only | 7,474.0 | ¥ | |
Mamas et al. | 2018 | Observational | 248,228 | England | 0.5 | All indications | 250.6 | £ |
Observational | 94,856 | England | 0.5 | Elective/Stable CAD only | 153.9 | £ | ||
Observational | 87,904 | England | 0.5 | NSTEMI/UA only | 282.2 | £ | ||
Observational | 65,468 | England | 0.5 | STEMI only | 348.3 | £ |
Abedlaal et al. [28] published a meta-analysis of randomized controlled trials (RCTs) and observational studies that demonstrated similar clinical outcomes for SDD versus overnight stay. Another meta-analysis [63]. published in 2017 also demonstrated similar findings. In a recently published meta-analysis of 11 studies with 21,687 patients, Lu et al. [64] have demonstrated that early and late clinical outcomes in patients discharged on the same day of PCI were comparable to those discharged after an overnight stay. While the clinical value of SDD is thus clearly established [65], the subsequent reductions in costs of PCI have not been systematically studied and are not clearly established.
Six studies [32, 33, 36, 41, 66, 67]. were eligible for meta-analysis of the
cost savings of SDD in the US. Notably, these studies represent research
published in the last three years (2017–2019). All the included studies were
observational in nature with prevalence of SDD varying widely from 1.6% to 50%
(two studies represented a matched comparison of SDD versus NSDD in a 1 : 1 or 1
: 2 proportion). Three studies [36, 41, 66] reported costs over the duration of
hospitalization while the other three studies [32, 33, 67] reported cumulative
30-days costs. The reported mean adjusted per-PCI cost savings in these studies
ranged from US
After inflation-correcting to year 2018 and using the random effects
meta-analytic framework, we estimated that the mean per-PCI cost savings of SDD
were US
Meta-analysis of the cost savings of SDD. (A) Forest plot of the published studies. Each study is color-coded. Boxes are proportional to the inverse-variance weights; error bars indicate 95% confidence intervals. Diamonds indicate the group-specific and overall summary effect size. (B) Boujat plot for the studies included in meta-analysis. Studies are color-coded and numbered to match the scheme in panel A.
Using univariable meta-regression we also investigated the potential contribution of cost period, prevalence of SDD, prevalence of TRI, average age, proportion of females and the proportion of elective PCIs on heterogeneity. We found that only cost period (hospitalization costs versus 30-day costs) reached statistical significance (P = 0.029) whereas none of the remaining putative predictors could adequately explain between-study heterogeneity.
Marso and Amin et al. [68] had conjectured that a combination of TRI
and SDD could be highly desirable. The Amin et al. [36] study first
demonstrated that the cost saving in patients who underwent TRI and SDD as
compared to those who underwent TFI and NSDD was US
A randomized controlled trial of SDD (the EPOS trial) in TFI patients from The
Netherlands (2007) first reported a cost saving of US
To our knowledge, this is the first systematic review and meta-analyses of the
cost savings associated with TRI and SDD in PCI. Our report makes the following
key observations: first, the cost savings of TRI from four US studies of 349,757
patients were US
According to the Institute of Medicine, an ideal healthcare system should
provide care that is safe, effective, efficient, equitable, timely and
patient-centered [71]. In this context, the appropriateness of both TRI and SDD
as candidate approaches to PCI care is self-evident. Both approaches are safe (as
shown by several previous studies and meta-analyses) [33, 72, 73, 74, 75]
effective as demonstrated by the associated cost savings shown here; efficient
(as demonstrated by studies on time demands of PCI options) [43, 76, 77, 78] and
patient-centered (since they both target patient satisfaction) [66]. In this
context, it is encouraging to note that the use of TRI in the United States is
rapidly increasing. The NCDR CathPCI Registry showed that in 2014 that the
prevalence of TRI had risen to 25% of all PCIs while the VA-CART Registry showed
a prevalence of 32% of TRI in 2018 [79, 80, 81]. However, even today most of the
patients still undergo TFI. Assuming a total of 900,000 PCIs nationally, even if
the TRI rate were to increase modestly from 30% to 50%, then we estimate a
national cost saving of 178.5 million US
The size of both the meta-analyses presented here also points towards a need for more studies in this domain. However, a glaring finding from our analyses is the paucity of randomized, controlled studies on the cost savings of both TRI and SDD (especially the latter). Most of the data that currently exists comes from observational studies. Whereas these observational studies have provided key insights into the econometrics of PCI, measured or unmeasured confounding can remain even if all the studies have rigorously adjusted for as many confounders as possible [82, 83]. In the future, large-scale multicenter randomized studies evaluating the costs of various care pathways (e.g., TRI/SDD) could provide a robust estimate of financial effects of these interventions. Combining TRI and SDD pathways is logical since, as shown by Koutouzis et al. [84], the main driver of SDD is TRI. These studies are essential for wide-ranging practice changes in the direction of TRI and SDD. Certainly, guidelines such as the 2021 ACC Expert Consensus Decision Pathway on Same-Day Discharge After Percutaneous Coronary Intervention by Rao et al. [85], also help increase the utilization of SDD after TRI.
While attempting to increase TRI in higher risk populations, one needs to bear in mind the risk of cross-over. In the MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox)-Access trial (NCT01433627) of 8404 patients with acute coronary syndrome who were randomized to radial or femoral access, access-site crossover from radial to femoral occurred in 183 of 4197 patients (4.4%). Crossing over from radial to femoral access abolished the bleeding benefit offered by the radial, where a ~2-fold higher rate of Bleeding Academic Research Consortium type (BARC) 3 or 5 bleeding was found among the femoral cross-over patients [86]. Thus, access site crossover occurs in a non-negligible proportion of patients undergoing PCI and may have a potential impact on clinical outcomes, costs, and time to discharge [86]. Whether vascular closure devices (VCDs) may reduce femoral artery complications is debated [87], and whether their use can narrow the gap in outcomes between radial and femoral access outcomes remains unclear [88]. In the same MATRIX trial, 30-day access site-related complications were evaluated between femoral access with VCDs, without VCDs and radial access [86]. They found the use of VCD does not reduce the risks of access site complications as compared with manual compression [86]. Access site complications with femoral access with or without the use of VCDs were equally high when compared with radial access [86]. Thus, VCDs did not mitigate the risk of access site complications and do not support the hypothesis that routine use of VCDs may narrow the gap between radial and femoral access. Lastly, evaluating the reasons for heterogeneity in studies related to SDD cost savings are limited in this meta-analysis due to a small number of studies. Although the duration of cost ascertainment (hospitalization versus 30-day costs) reached statistical significance and may be a contributor of the observed heterogeneity, it did not fully explain the residual heterogeneity. Other study characteristics such as age distribution, gender representation and TRI prevalence did not significantly contribute to the between-study heterogeneity. Thus, it appears that costs savings achieved due to SDD are consistent across patient characteristics such as age and gender and even TRI prevalence, but differ by the duration of cost ascertainment (hospitalization versus 30-day costs). As more studies on SDD accumulate, it may be possible to more comprehensively evaluate heterogeneity in the future.
There is adequate evidence to indicate that TRI can reduce hospitalization costs
of PCI by approximately US
HR and AA conceived and designed the study; HR performed the analysis; HR and AA interpreted the analysis; HR and AA wrote the paper; MT, JD, ER, MY and SL contributed to the manuscript revisions.
The institutional review board of the Washington University of St. Louis, MO approved the project and deemed it ‘not human subjects research’, exempt from informed consent. The IRB approval number is: IRB ID #: 201804060.
Not applicable.
Funding for the current study was provided by an unrestricted research grant from Terumo.
Dr. Amit P. Amin—has been funded via a comparative effectiveness research KM1 career development award from the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences of the National Institutes of Health, Grant Numbers UL1TR000448, KL2TR000450, TL1TR000449 and the National Cancer Institute of the National Institutes of Health, Grant Number 1KM1CA156708-01; an AHRQ R18 grant award (Grant Number R18HS0224181-01A1), an unrestricted grant from Terumo and is a consultant to Terumo.
No sponsor participated in the design and conduct of the study, collection, analysis, or interpretation of the data, nor in the preparation, review, nor approval of the manuscript. Drs. Amin and Kulkarni had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.